Colaluca, I.N.* ; Basile, A.* ; Freiburger, L. ; D'Uva, V.* ; Disalvatore, D.* ; Vecchi, M.* ; Confalonieri, S.* ; Tosoni, D.* ; Cecatiello, V.* ; Malabarba, M.G.* ; Yang, C.J.* ; Kainosho, M.* ; Sattler, M. ; Mapelli, M.* ; Pece, S.* ; di Fiore, P.P.*
A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
J. Cell Biol. 217, 745-762 (2018)
Numb functions as an oncosuppressor by inhibiting Notch signaling and stabilizing p53. This latter effect depends on the interaction of Numb with Mdm2, the E3 ligase that ubiquitinates p53 and commits it to degradation. In breast cancer (BC), loss of Numb results in a reduction of p53-mediated responses including sensitivity to genotoxic drugs and maintenance of homeostasis in the stem cell compartment. In this study, we show that the Numb-Mdm2 interaction represents a fuzzy complex mediated by a short Numb sequence encompassing its alternatively spliced exon 3 (Ex3), which is necessary and sufficient to inhibit Mdm2 and prevent p53 degradation. Alterations in the Numb splicing pattern are critical in BC as shown by increased chemoresistance of tumors displaying reduced levels of Ex3-containing isoforms, an effect that could be mechanistically linked to diminished p53 levels. A reduced level of Ex3-less Numb isoforms independently predicts poor outcome in BCs harboring wild-type p53. Thus, we have uncovered an important mechanism of chemoresistance and progression in p53-competent BCs.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Cell Fate; Mammalian Numb; Lung-cancer; Ubiquitin Ligase; Nmr Experiments; Histone H2ax; P53 Pathway; Case-cohort; Dna-damage; Mdm2
Keywords plus
Language
english
Publication Year
2018
Prepublished in Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
0021-9525
e-ISSN
1540-8140
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 217,
Issue: 2,
Pages: 745-762
Article Number: ,
Supplement: ,
Series
Publisher
Rockefeller University Press
Publishing Place
New York
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503000-001
Grants
Copyright
Erfassungsdatum
2018-02-21